Selected research
Industry Research
COPD Medicine Industry Research Report 2026
Market perspective
The global COPD Medicine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the COPD Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the COPD Medicine market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the COPD Medicine market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of COPD Medicine include GSK, Teva, Novartis, Merck, Roche, AstraZeneca, Viatris, Vertex and Sumitomo Dainippon, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global COPD Medicine market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to COPD Medicine.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
COPD Medicine Market by Company
GSK
Teva
Novartis
Merck
Roche
AstraZeneca
Viatris
Vertex
Sumitomo Dainippon
Chiesi
Boehringer Ingelheim
Beximco
COPD Medicine Segment by Type
Inhalable & Nasal Spray
Oral
Others
COPD Medicine Segment by Application
Hospital
Drugs Store
COPD Medicine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global COPD Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of COPD Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of COPD Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of COPD Medicine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Inhalable & Nasal Spray
- Oral
- Others
Applications
- Hospital
- Drugs Store
Companies covered
- GSK
- Teva
- Novartis
- Merck
- Roche
- AstraZeneca
- Viatris
- Vertex
- Sumitomo Dainippon
- Chiesi
- Boehringer Ingelheim
- Beximco
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 COPD Medicine by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Inhalable & Nasal Spray
- 2.2.3 Oral
- 2.2.4 Others
- 2.3 COPD Medicine by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Drugs Store
- 2.4 Assumptions and Limitations
3 COPD Medicine Breakdown Data by Type
- 3.1 Global COPD Medicine Historic Market Size by Type (2021-2026)
- 3.2 Global COPD Medicine Forecasted Market Size by Type (2027-2032)
4 COPD Medicine Breakdown Data by Application
- 4.1 Global COPD Medicine Historic Market Size by Application (2021-2026)
- 4.2 Global COPD Medicine Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global COPD Medicine Market Perspective (2021-2032)
- 5.2 Global COPD Medicine Growth Trends by Region
- 5.2.1 Global COPD Medicine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 COPD Medicine Historic Market Size by Region (2021-2026)
- 5.2.3 COPD Medicine Forecasted Market Size by Region (2027-2032)
- 5.3 COPD Medicine Market Dynamics
- 5.3.1 COPD Medicine Industry Trends
- 5.3.2 COPD Medicine Market Drivers
- 5.3.3 COPD Medicine Market Challenges
- 5.3.4 COPD Medicine Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top COPD Medicine Players by Revenue
- 6.1.1 Global Top COPD Medicine Players by Revenue (2021-2026)
- 6.1.2 Global COPD Medicine Revenue Market Share by Players (2021-2026)
- 6.2 Global COPD Medicine Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of COPD Medicine Head Office and Area Served
- 6.4 Global COPD Medicine Players, Product Type & Application
- 6.5 Global COPD Medicine Manufacturers Established Date
- 6.6 Global COPD Medicine Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America COPD Medicine Market Size (2021-2032)
- 7.2 North America COPD Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America COPD Medicine Market Size by Country (2021-2026)
- 7.4 North America COPD Medicine Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe COPD Medicine Market Size (2021-2032)
- 8.2 Europe COPD Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe COPD Medicine Market Size by Country (2021-2026)
- 8.4 Europe COPD Medicine Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific COPD Medicine Market Size (2021-2032)
- 9.2 Asia-Pacific COPD Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific COPD Medicine Market Size by Country (2021-2026)
- 9.4 Asia-Pacific COPD Medicine Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America COPD Medicine Market Size (2021-2032)
- 10.2 South America COPD Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America COPD Medicine Market Size by Country (2021-2026)
- 10.4 South America COPD Medicine Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa COPD Medicine Market Size (2021-2032)
- 11.2 Middle East & Africa COPD Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa COPD Medicine Market Size by Country (2021-2026)
- 11.4 Middle East & Africa COPD Medicine Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 GSK
- 12.1.1 GSK Company Information
- 12.1.2 GSK Business Overview
- 12.1.3 GSK Revenue in COPD Medicine Business (2021-2026)
- 12.1.4 GSK COPD Medicine Product Portfolio
- 12.1.5 GSK Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in COPD Medicine Business (2021-2026)
- 12.2.4 Teva COPD Medicine Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in COPD Medicine Business (2021-2026)
- 12.3.4 Novartis COPD Medicine Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Merck
- 12.4.1 Merck Company Information
- 12.4.2 Merck Business Overview
- 12.4.3 Merck Revenue in COPD Medicine Business (2021-2026)
- 12.4.4 Merck COPD Medicine Product Portfolio
- 12.4.5 Merck Recent Developments
- 12.5 Roche
- 12.5.1 Roche Company Information
- 12.5.2 Roche Business Overview
- 12.5.3 Roche Revenue in COPD Medicine Business (2021-2026)
- 12.5.4 Roche COPD Medicine Product Portfolio
- 12.5.5 Roche Recent Developments
- 12.6 AstraZeneca
- 12.6.1 AstraZeneca Company Information
- 12.6.2 AstraZeneca Business Overview
- 12.6.3 AstraZeneca Revenue in COPD Medicine Business (2021-2026)
- 12.6.4 AstraZeneca COPD Medicine Product Portfolio
- 12.6.5 AstraZeneca Recent Developments
- 12.7 Viatris
- 12.7.1 Viatris Company Information
- 12.7.2 Viatris Business Overview
- 12.7.3 Viatris Revenue in COPD Medicine Business (2021-2026)
- 12.7.4 Viatris COPD Medicine Product Portfolio
- 12.7.5 Viatris Recent Developments
- 12.8 Vertex
- 12.8.1 Vertex Company Information
- 12.8.2 Vertex Business Overview
- 12.8.3 Vertex Revenue in COPD Medicine Business (2021-2026)
- 12.8.4 Vertex COPD Medicine Product Portfolio
- 12.8.5 Vertex Recent Developments
- 12.9 Sumitomo Dainippon
- 12.9.1 Sumitomo Dainippon Company Information
- 12.9.2 Sumitomo Dainippon Business Overview
- 12.9.3 Sumitomo Dainippon Revenue in COPD Medicine Business (2021-2026)
- 12.9.4 Sumitomo Dainippon COPD Medicine Product Portfolio
- 12.9.5 Sumitomo Dainippon Recent Developments
- 12.10 Chiesi
- 12.10.1 Chiesi Company Information
- 12.10.2 Chiesi Business Overview
- 12.10.3 Chiesi Revenue in COPD Medicine Business (2021-2026)
- 12.10.4 Chiesi COPD Medicine Product Portfolio
- 12.10.5 Chiesi Recent Developments
- 12.11 Boehringer Ingelheim
- 12.11.1 Boehringer Ingelheim Company Information
- 12.11.2 Boehringer Ingelheim Business Overview
- 12.11.3 Boehringer Ingelheim Revenue in COPD Medicine Business (2021-2026)
- 12.11.4 Boehringer Ingelheim COPD Medicine Product Portfolio
- 12.11.5 Boehringer Ingelheim Recent Developments
- 12.12 Beximco
- 12.12.1 Beximco Company Information
- 12.12.2 Beximco Business Overview
- 12.12.3 Beximco Revenue in COPD Medicine Business (2021-2026)
- 12.12.4 Beximco COPD Medicine Product Portfolio
- 12.12.5 Beximco Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst